SCHEMBL4497449

SCHEMBL4497449

COc1ccc(CC(O)CCN2CCN(CC(=O)Nc3c(C)cccc3C)CC2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.55
TSHR P16473 2/20 0.55
CYP2D6 P10635 2/20 0.55
ADRB1 P08588 2/20 0.55
ADRA2A P08913 2/20 0.55
ADRA2B P18089 2/20 0.55
ADRA2C P18825 2/20 0.55
ADRA1A P35348 2/20 0.55
DRD3 P35462 2/20 0.55
HTR2B P41595 2/20 0.55
KCNH2 Q12809 2/20 0.55
NFKB1 P19838 1/20 0.55
ADRB2 P07550 1/20 0.55
SCN5A Q14524 1/20 0.55
LMNA P02545 2/20 0.54
BLM P54132 1/20 0.54
PMP22 Q01453 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6284296 0.90 CYP2D6 (0.64) CYP3A4TSHRCYP2D6ADRB1ADRA2A
SCHEMBL4501968 0.86 MEN1 (0.58) CYP3A4TSHRCYP2D6ADRB1ADRA2A
SCHEMBL4492926 0.85 CYP3A4 (0.57) CYP3A4TSHRCYP2D6ADRB1ADRA2A
SCHEMBL6285294 0.84 CYP2D6 (0.62) CYP3A4TSHRCYP2D6ADRB1ADRA2A
SCHEMBL4498033 0.83 CYP3A4 (0.64) CYP3A4TSHRCYP2D6ADRB1ADRA2A
SCHEMBL7078491 0.80 CYP2D6 (0.66) CYP3A4TSHRCYP2D6ADRB1ADRA2A
SCHEMBL6768741 0.80 CYP3A4 (0.65) CYP3A4TSHRCYP2D6ADRB1ADRA2A
SCHEMBL7281745 0.80 CYP2D6 (0.76) CYP3A4TSHRCYP2D6ADRB1ADRA2A
SCHEMBL6269531 0.79 TSHR (0.81) TSHRLMNAMEN1KMT2AUSP2
SCHEMBL3832856 0.78 MEN1 (0.64) CYP3A4TSHRCYP2D6ADRB1ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070155728-A1 Substituted Heterocyclic Compounds PALLE VENKATA 2007-07-05 US claimed
US-20040176356-A1 Substituted heterocyclic compounds CV THERAPEUTICS, INC. 2004-09-09 US claimed
US-7566717-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2009-07-28 US disclosed
US-20080275238-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS PALLE VENKATA 2008-11-06 US disclosed
US-20070155728-A1 Substituted Heterocyclic Compounds PALLE VENKATA 2007-07-05 US disclosed
US-7205303-B2 Substituted heterocyclic compounds CV THERAPEUTICS, INC. (US) 2007-04-17 US disclosed
EP-1578737-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS CV THERAPEUTICS, INC. (US) 2005-09-28 EP disclosed
US-20040176356-A1 Substituted heterocyclic compounds CV THERAPEUTICS, INC. 2004-09-09 US disclosed
WO-2004063180-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS CV THERAPEUTICS, INC. (US) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176356-A1 Substituted heterocyclic compounds KCNH1, KCNJ2, SCN5A CYP3A4 1273/4885TSHR 4124/4885CYP2D6 563/4885
US-20080275238-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS KCNH1, SDHA, COQ8A CYP3A4 598/4885TSHR 3785/4885CYP2D6 238/4885
US-20070155728-A1 Substituted Heterocyclic Compounds KCNH1, SDHA, COQ8A CYP3A4 598/4885TSHR 3785/4885CYP2D6 238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.